biopharma industry report biopharmaceuticals

Ensuring that the supply of qualified professionals is sufficient to meet demand will be the crucial step in successfully expanding the biopharma industry in Ireland.

The EGFSN (Expert Group on Future Skills Needs) estimates that 5,000 additional staff will be employed in biologics manufacturing by 2020. The number of professionals employed in the production of traditional pharmaceuticals will remain stable during this time; however, employment opportunities will continue due to the need for replacement staff.

biopharma test tubes

Combining replacement demand and growth there will be approximately 7,100 job openings from 2017 to 2020. Increasing the number of qualified graduates and attracting the right international talent is crucial if we are to ensure Ireland can meet the demand of its biopharma industry.

The biopharma sector employs significantly more third level graduates than the average industry. Over 46% of employees in the sector have a third level qualification, compared to a national average of 24%; and 25% of all PhD researchers working in industry are in the biopharma sector. According to the EGFSN there should be a sufficient supply of graduates in the medium term to meet industry demand. The EGFSN identified a short-term need for a number of technicians and senior process scientists within the industry, but this is not expected to be a factor in the long term as there are an appropriate number of training places to overcome this minor deficit.

biopharma employee wearing goggles

The Government initiated its ‘Smart Futures’ programme in 2012 with the aim of encouraging young people to pursue careers in Science Technology Engineering and Mathematics (STEM) related industries. The programme has been very successful at increasing the number of secondary students taking higher level maths, with record numbers opting for the higher level at both leaving and junior cert level this year. Since the introduction of the bonus points system for honours maths, the number of students sitting the exam has risen from 20% to 36% between 2011 and 2017. This is an important step in increasing the number of students entering STEM courses at third level. It is graduates from these courses that form the technical backbone of the biopharma industry so growing the volume of applicants to these courses is an important step in providing sufficient talent for the industry. Increasing the number of students taking higher level maths will lead to a greater take up of STEM courses at third level.

Given the long history of pharmaceutical manufacturing and the commitment of government and industry, we believe Ireland is in an excellent position to capitalise on this opportunity. The conditions are extremely favourable for any biopharma company considering establishing an operation in Ireland today.

 

To download our Biopharma Report in full click HERE.

To read other market insights click HERE or for opportunities within the biopharma sector visit our website collinsmcnicholas.ie.

Niall Murray Managing Director Collins McNicholas

 

 

 

 

Niall Murray

Managing Director

Collins McNicholas Recruitment & HR Services Group